This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • COVID-19
  • /
  • CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-T...
Clinical trial

CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)

Read time: 1 mins
Last updated:30th Jul 2021
Status: Active, not recruiting
Identifier: NCT04331808
CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI)

The overall objective of the study is to determine the therapeutic effect and tolerance of Tocizilumab in patients with moderate, severe pneumonia or critical pneumonia associated with Coronavirus disease 2019 (COVID-19). Tocilizumab (TCZ) is an anti-human IL-6 receptor monoclonal antibody that inhibits signal transduction by binding sIL-6R and mIL-6R. The study has a cohort multiple Randomized Controlled Trials (cmRCT) design. Randomization will occur prior to offering Tocilizumab administration to patients enrolled in the COVIMUNO-19 cohort. Tocilizumab will be administered to consenting adult patients hospitalized with CORVID-19 either diagnosed with moderate or severe pneumonia requiring no mechanical ventilation or critical pneumonia requiring mechanical ventilation. Patients who will chose not to receive Tocilizumab will receive standard of cares. Outcomes of Tocilizumab-treated patients will be compared with outcomes of standard of care treated patients as well as outcomes of patients treated with other immune modulators.

Study Type: Interventional (Clinical Trial)
Actual Enrollment: 228 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Tocilizumab Trial - CORIMUNO-19 - TOCI (CORIMUNO-TOCI)
Actual Study Start Date: March 30, 2020
Estimated Primary Completion Date: March 31, 2021
Estimated Study Completion Date: December 31, 2021

- Experimental: TOCILIZUMAB
- No Intervention: Standard of care

Category Value
Study type(s) Interventional
Expected enrolment 228
Actual Study start date 30 March 2020
Estimated Study Completion Date 31 December 2021

View full details